Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: A multicenter phase II study with dose adjustment according to baseline serum bilirubin level

European Journal of Cancer

Volumn 42, Issue 4, 2006, Pages 456-459

  Boige, Valérie ^a   Taïeb, Julien ^b   Hebbar, Mohamed ^c   Malka, David ^a   Debaere, Thierry ^a   Hannoun, Laurent ^b   Magherini, Emmanuelle ^d   Mignard, Dominique ^d   Poynard, Thierry ^b   Ducreux, Michel ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d SANOFI   (France)

Author keywords

Bilirubin; Chemotherapy; Cirrhosis; Hepatocellular carcinoma; Irinotecan; Phase II clinical trial

Indexed keywords

BILIRUBIN; IRINOTECAN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG ACTIVITY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HEART ARREST; HEPATIC ENCEPHALOPATHY; HUMAN; INFECTION; LIVER CELL CARCINOMA; MALE; MULTICENTER STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPTIC SHOCK; STATISTICAL SIGNIFICANCE; SURVIVAL; TUMOR BLEEDING; VOMITING;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BILIRUBIN; BIOLOGICAL MARKERS; CAMPTOTHECIN; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE;

EID: 32444431720     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.09.034     Document Type: Article

References (15)

1. J. Bruix, M. Sherman, and J.M. Llovet Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference, European Association for the Study of the Liver J Hepatol 35 2001 421 430
2. J. Bruix, M. Sala, and J.M. Llovet Chemoembolization for hepatocellular carcinoma Gastroenterology 127 5 Suppl. 1 2004 S179 S188
3. A.K. Nowak, P.K. Chow, and M. Findlay Systemic therapy for advanced hepatocellular carcinoma: a review Eur J Cancer 40 2004 1474 1484
4. P.N. Adjei, S.H. Kaufmann, and W.Y. Leung Selective induction of apoptosis in Hep 3B cells by topoisomerase I inhibitors: evidence for a protease-dependent pathway that does not activate cysteine protease P32 J Clin Invest 98 1996 2588 2596
5. V.I. Khaoustov, A. Ozer, and J.R. Smith Induction of senescent cell-derived inhibitor of DNA synthesis gene (SDI1), in hepatoma (HepG2) cells arrested in the G2-phase of the cycle by 9-nitrocamptothecin Lab Invest 73 1995 118 127
6. E.M. O'Reilly, K.E. Stuart, and P.M. Sanz-Altamira A phase II study of irinotecan in patients with advanced hepatocellular carcinoma Cancer 91 2001 101 105
7. J.M. Gornet, D. Azoulay, J.C. Duclos-Vallée, and F. Goldwasser Complete remission of unresectable hepatocellular carcinoma on healthy liver by the combination of aggressive surgery and high-dose-intensity chemotherapy by CPT-11 Anticancer Drugs 11 2000 649 652
8. E. Raymond, V. Boige, and S. Faivre Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction J Clin Oncol 20 2002 4303 4312
9. G.G. Chabot, D. Abigerges, and G. Catimel Population pharmacokinetics of irinotecan (CPT11) and active metabolite SN38 during phase I studies Ann Oncol 6 1995 141 151
10. A.B. Miller, B. Hoogstraten, M. Staquet, and A. Winkler Reporting results of cancer treatment Cancer 47 1981 207 214
11. E.A. Gehan The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent J Chronic Dis 13 1961 346 353
12. P. Rougier, R. Bugat, and J.Y. Douillard Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy J Clin Oncol 15 1997 251 260
13. E. Van Cutsem, D. Cunningham, and W.W. Ten Bokkel Huinink Clinical activity and benefit of irinotecan (CPT11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU) Eur J Cancer 35 1999 54 59
14. J.P. Villeneuve, and V. Pichette Cytochrome P450 and liver diseases Curr Drug Metab 5 2004 273 282
15. Y. Motoyama Studies of human liver bilirubin-glycosyl transferase. Bilirubin UDP-xylosyl and UDP-glucuronyl transferase activities in diseased human livers Enzyme 24 1979 158 162